Current status of prostaglandins for cervical ripening

Javine McLaughlin, Lawrence D Devoe

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To review the safety and efficacy of administering various prostaglandin formulations to achieve cervical ripening and spontaneous vaginal delivery in women near or at term. STUDY DESIGN: Peer reviewed clinical research articles in English and searchable on PubMed.com. A thorough literature search was conducted on PubMed. com using the following terms: [misoprostol], [dinoprostone], [prostaglandin E1], [prostaglandin E2], [PGE1], [PGE2], [cervical ripening], [induction of labor]. RESULTS: The review shows conflicting opinions concerning the safety and efficacy of current standard-of care formulations for cervical ripening. A gold standard option for optimal treatment has not been confirmed. CONCLUSION: While the clinical evidence suggests that prostaglandin E 1 (PGE 1 ) and E 2 (PGE 2 ) both could be used for cervical ripening when no contraindications are present, PGE 2 formulations remain the only commercially available prostaglandin products for cervical ripening approved by the U.S. Food and Drug Administration. We conclude that more research is warranted on the risks of treatment-emergent adverse events and serious complications during induction of labor.

Original languageEnglish (US)
Pages (from-to)221-228
Number of pages8
JournalJournal of Reproductive Medicine
Volume62
Issue number3
StatePublished - Jan 1 2017

Fingerprint

Cervical Ripening
Prostaglandins
Induced Labor
Alprostadil
Prostaglandins E
Dinoprostone
PubMed
Safety
Misoprostol
United States Food and Drug Administration
Standard of Care
Research
Therapeutics

Keywords

  • Cervical ripening
  • Dinoprostone
  • Labor induction
  • Misoprostol
  • PGE1
  • PGE2
  • Prostaglandin
  • Prostaglandin E
  • Receptors
  • Review

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Current status of prostaglandins for cervical ripening. / McLaughlin, Javine; Devoe, Lawrence D.

In: Journal of Reproductive Medicine, Vol. 62, No. 3, 01.01.2017, p. 221-228.

Research output: Contribution to journalArticle

@article{a5843ddcbb994a308431035a0991f5ab,
title = "Current status of prostaglandins for cervical ripening",
abstract = "OBJECTIVE: To review the safety and efficacy of administering various prostaglandin formulations to achieve cervical ripening and spontaneous vaginal delivery in women near or at term. STUDY DESIGN: Peer reviewed clinical research articles in English and searchable on PubMed.com. A thorough literature search was conducted on PubMed. com using the following terms: [misoprostol], [dinoprostone], [prostaglandin E1], [prostaglandin E2], [PGE1], [PGE2], [cervical ripening], [induction of labor]. RESULTS: The review shows conflicting opinions concerning the safety and efficacy of current standard-of care formulations for cervical ripening. A gold standard option for optimal treatment has not been confirmed. CONCLUSION: While the clinical evidence suggests that prostaglandin E 1 (PGE 1 ) and E 2 (PGE 2 ) both could be used for cervical ripening when no contraindications are present, PGE 2 formulations remain the only commercially available prostaglandin products for cervical ripening approved by the U.S. Food and Drug Administration. We conclude that more research is warranted on the risks of treatment-emergent adverse events and serious complications during induction of labor.",
keywords = "Cervical ripening, Dinoprostone, Labor induction, Misoprostol, PGE1, PGE2, Prostaglandin, Prostaglandin E, Receptors, Review",
author = "Javine McLaughlin and Devoe, {Lawrence D}",
year = "2017",
month = "1",
day = "1",
language = "English (US)",
volume = "62",
pages = "221--228",
journal = "Journal of Reproductive Medicine",
issn = "0024-7758",
publisher = "Donna Kessel",
number = "3",

}

TY - JOUR

T1 - Current status of prostaglandins for cervical ripening

AU - McLaughlin, Javine

AU - Devoe, Lawrence D

PY - 2017/1/1

Y1 - 2017/1/1

N2 - OBJECTIVE: To review the safety and efficacy of administering various prostaglandin formulations to achieve cervical ripening and spontaneous vaginal delivery in women near or at term. STUDY DESIGN: Peer reviewed clinical research articles in English and searchable on PubMed.com. A thorough literature search was conducted on PubMed. com using the following terms: [misoprostol], [dinoprostone], [prostaglandin E1], [prostaglandin E2], [PGE1], [PGE2], [cervical ripening], [induction of labor]. RESULTS: The review shows conflicting opinions concerning the safety and efficacy of current standard-of care formulations for cervical ripening. A gold standard option for optimal treatment has not been confirmed. CONCLUSION: While the clinical evidence suggests that prostaglandin E 1 (PGE 1 ) and E 2 (PGE 2 ) both could be used for cervical ripening when no contraindications are present, PGE 2 formulations remain the only commercially available prostaglandin products for cervical ripening approved by the U.S. Food and Drug Administration. We conclude that more research is warranted on the risks of treatment-emergent adverse events and serious complications during induction of labor.

AB - OBJECTIVE: To review the safety and efficacy of administering various prostaglandin formulations to achieve cervical ripening and spontaneous vaginal delivery in women near or at term. STUDY DESIGN: Peer reviewed clinical research articles in English and searchable on PubMed.com. A thorough literature search was conducted on PubMed. com using the following terms: [misoprostol], [dinoprostone], [prostaglandin E1], [prostaglandin E2], [PGE1], [PGE2], [cervical ripening], [induction of labor]. RESULTS: The review shows conflicting opinions concerning the safety and efficacy of current standard-of care formulations for cervical ripening. A gold standard option for optimal treatment has not been confirmed. CONCLUSION: While the clinical evidence suggests that prostaglandin E 1 (PGE 1 ) and E 2 (PGE 2 ) both could be used for cervical ripening when no contraindications are present, PGE 2 formulations remain the only commercially available prostaglandin products for cervical ripening approved by the U.S. Food and Drug Administration. We conclude that more research is warranted on the risks of treatment-emergent adverse events and serious complications during induction of labor.

KW - Cervical ripening

KW - Dinoprostone

KW - Labor induction

KW - Misoprostol

KW - PGE1

KW - PGE2

KW - Prostaglandin

KW - Prostaglandin E

KW - Receptors

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=85019599880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019599880&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85019599880

VL - 62

SP - 221

EP - 228

JO - Journal of Reproductive Medicine

JF - Journal of Reproductive Medicine

SN - 0024-7758

IS - 3

ER -